Table 3. Percentage of patients in the validation cohort and in the derivation-plus-validation cohort with an ideal, underestimated, or overestimated dose of tacrolimus in renal transplant patients requiring low, intermediate, or high actual doses of tacrolimus.

Actual Dose Required	N/o. of Patients (%)	Ideal Dose* (%)	Underestimation&	Overestimation$ (%)
Validation cohort only	126	54.8	19.8	25.4
≤2.5 mg/day	32	31.2	0	68.8
>2.5 mg/day to ≤4 mg/day	69	72.5	14.5	13.0
>4 mg/day	25	36.0	60.0	4.0
Derivation-plus-validation cohort	693	57.3	19.2	23.4
≤2.5 mg/day	169	38.5	0	61.5
>2.5 mg/day to ≤4 mg/day	380	70.5	14.4	15.0
>4 mg/day	144	44.4	54.9	0.7

^*The ideal dose was defined as a predicted dose that was within 20% of the actual stable therapeutic dose of tacrolimus. ^&We defined underestimation as a predicted dose that was at least 20% lower than the actual stable dose. ^$We defined overestimation as a predicted dose that was at least 20% higher than the actual stable dose.